Biomarkers of therapeutic response in multiple sclerosis: current status.

Mol Diagn Ther · 2014 · PMC4245485 · PMID 25164543

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

The decrease in CSF fetuin-A levels in natalizumab-treated patients was highly significant over 6 and 12 months, compared with baseline pre-treatment levels [ 20 ].

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.